more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$116.17 USD

+0.71 (0.61%)

Updated Sep 3, 2024 04:00 PM ET

After-Market: $116.20 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

Top 33% (84 out of 251)

Industry: Medical - Products

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

Is a Surprise Coming for Zimmer Biomet (ZBH) This Earnings Season?

by Zacks Equity Research Published on August 03,2020

Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ZBHPositive Net Change

medical

Will Zimmer (ZBH) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research Published on July 31,2020

Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ZBHPositive Net Change

Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research Published on July 28,2020

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ZBHPositive Net Change

Zimmer Biomet (ZBH) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research Published on July 28,2020

Zimmer Biomet's (ZBH) Hips and Knees portfolios are expected to have contributed to second-quarter top line despite pandemic-led business disruptions.

3 Growth-Focused MedTech Stocks to Buy Amid Coronavirus Crisis

by Sriparna Ghosal Published on July 10,2020

Once the pandemic-led crisis is over, these MedTech growth-focused stocks will flourish on a number of positive developments.

medical

3 Affordable MedTech Growth Stocks to Buy Amid Market Unrest

by Debanjana Dey Published on July 08,2020

Here are some MedTech stocks which might be a solid investment option amid the coronavirus-battered market conditions.

medical

3 Cheap MedTech Stocks Set to Gain Once Coronavirus Crisis Ebbs

by Sriparna Ghosal Published on July 06,2020

Once the pandemic-led crisis eases, these MedTech stocks will likely flourish on the back of number of positive developments.

medical

Medical Products Industry's Near-Term Outlook Lacks Spark

by Trina Mukherjee Published on July 03,2020

AI & Robotics can drive the medical products industry amid the coronavirus-induced crisis.

medical

Zimmer Biomet Adds New Features to mymobility with Apple Watch

by Zacks Equity Research Published on June 23,2020

Zimmer Biomet (ZBH) expands mymobility digital platform by leveraging Apple's ecosystem to enhance patients' post-operative care.

The Smart Future: Will Robotics Call the Shots Post Coronavirus?

by Zacks Equity Research Published on June 11,2020

Robots are assisting in surprising ways on the COVID frontline. With their pivotal role in battling the coronavirus, robotics revolution is swiftly gaining momentum and soon might be the new normal.

Zimmer (ZBH) Up 18.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research Published on June 10,2020

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ZBHPositive Net Change

Should iShares Morningstar MidCap Value ETF (JKI) Be on Your Investing Radar?

by Sweta Killa Published on June 05,2020

Style Box ETF report for JKI

Zimmer Biomet Faces Procedure Delays, Long-Term Potential Solid

by Zacks Equity Research Published on May 29,2020

Zimmer Biomet (ZBH) believes COVID-19 to continue to have a significant unfavorable impact on its sales in the near term.

medical

Zimmer Biomet (ZBH) Q1 Earnings Top, Revenues Miss Estimates

by Zacks Equity Research Published on May 11,2020

The spread of coronavirus results in deferral of elective procedures for Zimmer Biomet (ZBH) in Q1.

medical

Zimmer Biomet (ZBH) Beats Q1 Earnings Estimates

by Zacks Equity Research Published on May 11,2020

Zimmer (ZBH) delivered earnings and revenue surprises of 22.30% and -0.34%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?